Detalles de la búsqueda
1.
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Future Oncol
; 20(8): 447-458, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882460
2.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36546453
3.
Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study).
J Infect Dis
; 226(3): 386-395, 2022 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417015
4.
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Ann Hematol
; 98(12): 2749-2760, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31745601
5.
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Oncologist
; 23(3): 279-287, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29192016
6.
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Eur J Haematol
; 101(4): 556-565, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30027641
7.
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
Ann Hematol
; 96(10): 1681-1691, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762081
8.
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Am J Hematol
; 92(8): E146-E152, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28474745
9.
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
Clin Lymphoma Myeloma Leuk
; 24(4): 224-231.e2, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212206
10.
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 41(4): 1576-1593, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402374
11.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 41(2): 696-715, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38110653
12.
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Haematologica
; 103(5): e204-e206, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29419428
13.
Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis.
J Dermatolog Treat
; 34(1): 2169574, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36724798
14.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Cancers (Basel)
; 15(22)2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001589
15.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 39(1): 81-89, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271807
16.
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Adv Ther
; 40(3): 1187-1203, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36652175
17.
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Adv Ther
; 40(5): 2412-2425, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36961654
18.
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Adv Ther
; 39(1): 518-531, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34797506
19.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): 690-701, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764490
20.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clin Drug Investig
; 42(1): 29-41, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34822128